Skip to content

In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

CPReboa: In-hospital Cardiopulmonary Resuscitation With Balloon Occlusion of the Descending Aorta

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07434726
Acronym
CPReboa
Enrollment
98
Registered
2026-02-27
Start date
2026-04-14
Completion date
2030-12-01
Last updated
2026-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest

Keywords

Cardiac Arrest, resuscitative endovascular occlusion of the aorta REBOA, cardio pulmonary resuscitation CPR, advanced cardiac life support ACLS

Brief summary

This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.

Detailed description

Patients with in-hospital cardiac arrest (IHCA) outside the operating room, the coronary angiography suite and the intensive care unit (ICU) will be attended to by the hospitals resuscitation team and provided with advanced cardiac life support (ACLS) as per usual practice. A research team will be deployed simultaneously and, when patients meet inclusion criteria, will randomize patients to ACLS alone or to ACLS plus balloon occlusion of the descending thoracic aorta by means of a resuscitative endovascular occlusion of the aorta (REBOA) catheter.

Interventions

DEVICEresuscitative endovascular occlusion of the aorta (REBOA)

Insertion of a balloon catheter through the common femoral artery, retrograde advancement of the catheter into the descending thoracic aorta, ballon occlusion of the aorta

Advanced Cardiac Life Support (ACLS) as per American Heart Association (AHA) or European Resuscitation Council (ERC) standards

Sponsors

Insel Gruppe AG, University Hospital Bern
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients suffering from in hospital cardiac arrest (IHCA), including patients with out of hospital cardiac arrest (OHCA) and return of spontaneous circulation (ROSC), transported to the emergency department, where they suffer a second arrest (IHCA) * successful placement of a femoral artery introducer sheath * any electrical cardiac activity seen in the initial rhythm analysis * ongoing effort of resuscitation as determined by study-independent resuscitation lead

Exclusion criteria

* IHCA in the operating room, on intensive care unit or in the cardiac catheter laboratory * hospital visitors suffering from cardiac arrest * asystole seen in the initial rhythm analysis * (presumed) age under 18 years * known "do not resuscitate"-order * known or obvious pregnancy * traumatic cardiac arrest * known aortic pathologies that render cannulation impossible * known allergies to radiographic contrast agents

Design outcomes

Primary

MeasureTime frameDescription
Sustained ROSCUp to 1 hour after study inclusionAny return of spontaneous circulation lasting longer then 20 minutes

Secondary

MeasureTime frameDescription
Survival to hospital dischargeat hospital discharge, up to 90 days after study inclusiondead or alive
Survival to six month6 month after study inclusiondead or alive
neurologic outcome at the time of 30 daysDay 30 after study inclusionmeasured by means of modified ranking scale
neurologic outcome at the time of six month6 month after study inclusionmeasured by means of modified ranking scale
ICU-free days before hospital dischargeat hospital discharge, up to 90 days after study inclusion
ICU-free days at 30 days30 days after study inclusion

Countries

Switzerland

Contacts

CONTACTTanja Birrenbach, MD, MME
tanja.birrenbach@insel.ch+41 31 632 57 01
CONTACTCornelia Lammbrigger, RN
ukn.studynurse@insel.ch+41 31 632 57 01
PRINCIPAL_INVESTIGATORTanja Birrenbach, MD, MME

Inselspital University Hospital Bern

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 22, 2026